| Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer F Tas, D Duranyildiz, A Argon, H Oğuz, H Camlica, V Yasasever, E Topuz Medical oncology 22, 353-358, 2005 | 106 | 2005 |
| Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer D Derin, HO Soydinç, N Guney, F Tas, H Çamlıca, D Duranyıldız, ... Lung cancer 59 (2), 240-245, 2008 | 101 | 2008 |
| Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients F Tas, D Duranyildiz, H Oguz, H Camlica, V Yasasever, E Topuz Melanoma research 16 (5), 405-411, 2006 | 90 | 2006 |
| Serum IL-8 and IL-12 levels in breast cancer D Derin, HO Soydinc, N Guney, F Tas, H Camlica, D Duranyildiz, ... Medical oncology 24, 163-168, 2007 | 84 | 2007 |
| Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer F Tas, D Duranyildiz, H Oguz, H Camlica, V Yasasever, E Topuz Cancer investigation 24 (5), 492-496, 2006 | 82 | 2006 |
| Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer F Tas, D Duranyildiz, H Oguz, H Camlica, V Yasasever, E Topuz Cancer investigation 24 (6), 576-580, 2006 | 71 | 2006 |
| Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma F Tas, D Duranyildiz, H Oguz, H Camlica, V Yasasever, E Topuz Medical Oncology 25, 431-436, 2008 | 62 | 2008 |
| The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in … F Tas, H Oguz, A Argon, D Duranyildiz, H Camlica, V Yasasever, E Topuz Medical oncology 22, 241-246, 2005 | 53 | 2005 |
| Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer N Guney, HO Soydinc, D Derin, F Tas, H Camlica, D Duranyildiz, ... Medical Oncology 25, 194-200, 2008 | 44 | 2008 |
| Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced … F Tas, D Duranyildiz, HO Soydinc, I Cicin, M Selam, K Uygun, R Disci, ... Cancer chemotherapy and pharmacology 61, 721-725, 2008 | 41 | 2008 |
| Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin’s lymphoma N Guney, HO Soydinc, M Basaran, S Bavbek, D Derin, H Camlica, ... Asian Pac J Cancer Prev 10 (4), 669-674, 2009 | 40 | 2009 |
| Macrophage migration inhibitory factor in cancer V Yasasever, H Camlica, D Duranyildiz, H Oguz, F Tas, N Dalay Cancer investigation 25 (8), 715-719, 2007 | 40 | 2007 |
| Serum bcl-2 and survivin levels in melanoma F Tas, D Duranyildiz, A Argon, H Oguz, H Camlica, V Yasasever, E Topuz Melanoma research 14 (6), 543-546, 2004 | 35 | 2004 |
| Serum levels of angiogenic factors in early breast cancer remain close to normal D Duranyildiz, H Camlica, HO Soydinc, D Derin, V Yasasever The Breast 18 (1), 26-29, 2009 | 31 | 2009 |
| Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases F Tas, D Duranyildiz, H Oguz, H Camlica, V Yasasever, E Topuz Medical Oncology 25, 346-349, 2008 | 29 | 2008 |
| The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer H Camlica, D Duranyildiz, H Oguz, EN Oral, V Yasasever Pathology & Oncology Research 14, 79-83, 2008 | 29 | 2008 |
| Variations in systemic biomarkers of oxidative/nitrosative stress and DNA damage before and during the consequent two cycles of chemotherapy in breast cancer patients P Atukeren, B Yavuz, HO Soydinc, S Purisa, H Camlica, MK Gumustas, ... Clinical chemistry and laboratory medicine 48 (10), 1487-1495, 2010 | 27 | 2010 |
| Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma S Karabulut, F Tas, F Akyüz, AC Ormeci, M Serilmez, HO Soydinç, ... Tumor Biology 35, 2327-2333, 2014 | 24 | 2014 |
| For which cancer types can neuron-specific enolase be clinically helpful in Turkish patients? E Bilgin, Y Dizdar, M Serilmez, HO Soydinc, CT Yasasever, D Duranyildiz, ... Asian Pacific Journal of Cancer Prevention 14 (4), 2541-2544, 2013 | 21 | 2013 |
| Matrix metalloproteinase-9 decreased after chemotherapy in patients with non-small cell lung cancer E Ertan, H Soydinc, A Yazar, Z Ustuner, F Tas, V Yasasever Tumori Journal 97 (3), 286-289, 2011 | 21 | 2011 |
